Cabaletta Bio, Inc. Common Stock
Here’s whether Cabaletta Bio, Inc. Common Stock (CABA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); strong 1-year return of +95.6%; rising volume confirms the move (1.39x 30d avg). Concerns: 50-day MA is falling (-3.73% over 10 days); RSI 72 — overbought, elevated pullback risk; 3-month momentum negative (-14.2%). Currently 26.0% off its 52-week high. Score: +2/7.
CABA is in a confirmed uptrend, trading above both its 50-day ($2.88) and 200-day ($2.87) moving averages. With an RSI of 72.5, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +95.6% compares to +20.5% for SPY (beat the market by 75.1%). The current 26.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.